NEWARK,
Calif., May 11, 2023 /PRNewswire/ -- Protagonist
Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today
announced that additional data from the REVIVE study of rusfertide
in polycythemia vera will be presented in two posters at the annual
Congress of the European Hematology Association (EHA), taking place
June 8-11, 2023 in Frankfurt, Germany and virtually through
June 15, 2023.
Details are as follows:
Title: Rusfertide (PTG-300) improves polycythemia
vera (PV) related symptoms in PV patients
Abstract Code: P1016
Presenting Author: Andrew
Kuykendall, M.D., Assistant Member, Department of Malignant
Hematology, Moffitt Cancer Center
Session Date and Time: Friday, June 9,
18:00-19:00 CEST
Title: Pharmacokinetic and pharmacodynamic effects of
rusfertide in polycythemia vera: Results from an ongoing Phase 2
study in patients with elevated hematocrit values
Abstract Code: P1048
Presenting Author: Marina
Kremyanskaya, M.D., Ph.D., Assistant Professor of Medicine,
Hematology and Medical Oncology, Icahn School of Medicine at Mount
Sinai
Session Date and Time: Friday, June
9, 18:00-19:00 CEST
Full abstract information can be found on the EHA 2023 Hybrid
Congress website at
https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with
peptide-based new chemical entities rusfertide and JNJ-2113
(formerly PN-235) in advanced stages of clinical development, both
derived from the Company's proprietary technology platform.
Rusfertide, a mimetic of the natural hormone hepcidin, is the
Company's lead drug candidate currently in a global Phase 3 stage
of development. The REVIVE study is now complete, with an
open-label extension underway. The global Phase 3 VERIFY study of
rusfertide in polycythemia vera is ongoing. Protagonist retains all
worldwide development and commercialization rights to
rusfertide.
Positive topline results from the FRONTIER 1 study of JNJ-2113
in moderate-to-severe plaque psoriasis became available in
March 2023, with further details to
be shared at medical meetings starting in the second quarter of
2023. Advancement of JNJ-2113 into a Phase 3 study and meeting the
primary endpoint in that study would qualify Protagonist for
milestone payments of $50 million and
$115 million, respectively. In total,
Protagonist remains eligible for up to $855
million in various milestone payments and tiered royalties
based on worldwide net drug sales.
More information on Protagonist, its pipeline drug candidates
and clinical studies can be found on the Company's website at
protagonist-inc.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our expectations regarding our cash
runway, and potential benefits of rusfertide and JNJ-2113. In some
cases, you can identify these statements by forward-looking words
such as "anticipate," "believe," "may," "will," "expect," or the
negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, our ability to develop and
commercialize our product candidates, delays or difficulties
in enrolling or completing clinical studies, the potential that
results from clinical or non-clinical studies indicate our
compounds or product candidates are unsafe or ineffective,
dependence on third parties to conduct clinical studies and
manufacture our products, our ability to earn milestone
payments under our collaboration agreement with Janssen Biotech,
the impact of the current COVID-19 pandemic on our discovery and
development efforts, impact of natural disasters and the impact of
the ongoing military conflict in Ukraine and Russia on any future studies, our ability to
use and expand our programs to build a pipeline of product
candidates, our ability to obtain and maintain regulatory approval
of our product candidates, our ability to operate in a competitive
industry and compete successfully against competitors that have
greater resources than we do, and our ability to obtain and
adequately protect intellectual property rights for our product
candidates. Additional information concerning these and other
risk factors affecting our business can be found in our periodic
filings with the Securities and Exchange Commission, including
under the heading "Risk Factors" contained in our most recently
filed periodic reports on Form 10-K and Form 10-Q filed
with the Securities and Exchange Commission. Forward-looking
statements are not guarantees of future performance, and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in
this press release speak only as of the date of this press release.
We assume no obligation to update our forward-looking statements,
whether as a result of new information, future events or otherwise,
after the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-presentations-at-the-2023-annual-congress-of-the-european-hematology-association-301822327.html
SOURCE Protagonist Therapeutics, Inc.